This US-based infectious disease specialist discusses the disease burden of RSV, marketed vaccines and antibody therapies used in key risk groups, the anticipated revaccination schedule for RSV vaccination, and the potential for combination vaccines that encompass RSV in combination with other infectious diseases. 

This interview was conducted on 26 July 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.